利福平、氯法齐明和B1912对海分枝杆菌作用的体外和体内研究。

In vitro and in vivo studies of the action of rifampicin, clofazimine and B1912 on Mycobacterium marinum.

作者信息

Banerjee D K, Holmes I B

出版信息

Chemotherapy. 1976;22(3-4):242-52. doi: 10.1159/000221931.

DOI:10.1159/000221931

Abstract

Rifampicin (RMP) and two riminophenazine compounds (B663 and B1912) suppressed the growth of Mycobacterium marinum in vitro and in a mouse footpad infection. At appropriate concentrations and dietary dosage, all three drugs showed bactericidal activity in vitro and in vivo. On the basis of minimum inhibitory concentration, RMP was considerably more active than the other two substances in vitro. However, the rate of bactericidal effect was similar for all three drugs. In vivo, the minimum bactericidal dietary dosages of RMP, B663 and B1912 were 0.03, 0.03 and less than or equal to 0.01%, respectively. Results suggest that these drugs may be of value for the treatment of clinical M. marinum infections.

摘要

利福平（RMP）和两种苯并吩嗪化合物（B663和B1912）在体外以及小鼠足垫感染模型中均能抑制海分枝杆菌的生长。在适当的浓度和饮食剂量下，这三种药物在体外和体内均表现出杀菌活性。基于最低抑菌浓度，RMP在体外的活性明显高于其他两种物质。然而，三种药物的杀菌效果速率相似。在体内，RMP、B663和B1912的最低杀菌饮食剂量分别为0.03%、0.03%和小于或等于0.01%。结果表明，这些药物可能对临床海分枝杆菌感染的治疗具有价值。